27-Feb-2025 3:01 PM CST - Business Wire Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. 2024 was an exceptional year for Janux as we displayed t
27-Feb-2025 3:01 PM CST - Business Wire Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. 2024 was an exceptional year for Janux as we displayed t
